BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Biogen Inc. Secures Global Rights To Felzartamab Through Greater China Deal With TJ Biopharma

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one...

April 21, 2026 | News

Datasea Delivers AI Multimodal Projects Worth RMB 6.9 Million To Accelerate High Margin Shift

Completed Projects Further Support the Company's Transition Toward High-Margin, Solution-Driven Revenue and Strengthen Customer Stickiness Across AI Multim...

April 21, 2026 | News

Mabwell Secures JFDA GMP Compliance For Denosumab Biosimilars, Marking PIC S Milestone

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that its wholly-owned subsidiary, T-m...

April 21, 2026 | News

Mabwell Secures NMPA IND Acceptance For First In Class LILRB4 CD3 Bispecific Antibod

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Ad...

April 17, 2026 | News

Mabwell Advances Alpha Synuclein PET Tracer Into Phase I Strengthening Early Diagnosis Of Neurodegenerative Disorders

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that 18F-FD4 (R&D code: SST0...

April 16, 2026 | News

WuXi Biologics Secures ISO 13485 Certification With Zero Non Conformities Strengthening Combination Product Capabilities

WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has successfully ...

April 16, 2026 | News

DualityBio Secures NMPA Review For Trastuzumab Pamirtecan In HER2 Positive Breast Cancer

DualityBio announced that the Biologics License Application (BLA) for the investigational antibody-drug conjugate ("ADC") trastuzumab pamirtecan ("T-Pam", ...

April 14, 2026 | News

Haisco Partners With AbbVie To Advance Global Pain Therapeutics Pipeline

Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV), a...

April 14, 2026 | News

Lynk Pharmaceuticals Secures China NDA Acceptance For Zemprocitinib In Atopic Dermatitis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammat...

April 13, 2026 | News

Shanghai Ark Biopharmaceutical Advances First In Human Trial Of Long Acting Influenza Therapy AK0406

Shanghai Ark Biopharmaceutical Co., Ltd. announced that the first cohort of healthy volunteers has been dosed in a phase I clinical trial of AK0406, a nove...

April 13, 2026 | News

Vivatides Secures USD 54 Million Series A To Advance Next Generation RNA Therapeutics Beyond Liver Targets

Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies Vivatides Therapeutics, a global biotechnology ...

April 13, 2026 | News

Everest Medicines To Acquire Hasten Biopharmaceuticals Singapore Unit In USD 250 Million Deal

Accelerates Asia Pacific expansion by acquiring a ready-built regional commercial platform with 14 marketed chronic disease products Aggregate considera...

April 09, 2026 | News

ATLATL And Daiichi Sankyo Partner To Advance APAC Driven Biopharma Innovation

ATLATL Innovation Center (hereinafter referred to as "ATLATL"), a global innovation platform for life science research and development, announced an agreem...

April 09, 2026 | News

Alphamab Oncology Reports Phase III Success For Anbenitamab In HER2 Positive Breast Cancer

Alphamab Oncology announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed wit...

April 06, 2026 | News

Stay Connected